Royal Bank of Canada reissued their outperform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research note released on Wednesday morning, Benzinga reports. They currently have a $24.00 target price on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on the stock. Truist Financial cut […]